Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 15, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $81.33 to $19,200,000.00.

Highlighted Stocks Traded by Insiders:

Mead Johnson Nutrition (MJN) - FREE Research Report

Golsby Stephen W, who is Director at Mead Johnson Nutrition, sold 5,000 shares at $99.11 on Jan. 15, 2015. Following this transaction, the Director owned 20,458 shares meaning that the stake was reduced by 19.64% with the 5,000-share transaction.

The shares most recently traded at $99.22, up $0.11, or 0.11% since the insider transaction. Historical insider transactions for Mead Johnson Nutrition go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 8,874
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 42,489
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 99,013

The average volume for Mead Johnson Nutrition has been 1.2 million shares per day over the past 30 days. Mead Johnson Nutrition has a market cap of $19.9 billion and is part of the consumer goods sector and food & beverage industry. Shares are down 1.98% year-to-date as of the close of trading on Thursday.

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children's nutrition, and other nutritional products. The stock currently has a dividend yield of 1.52%. The company has a P/E ratio of 29.5. Currently, there are 5 analysts who rate Mead Johnson Nutrition a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MJN - FREE

TheStreet Quant Ratings rates Mead Johnson Nutrition as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mead Johnson Nutrition Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C, who is Chairman and CEO at Jazz Pharmaceuticals, sold 5,000 shares at $161.73 on Jan. 15, 2015. Following this transaction, the Chairman and CEO owned 554,131 shares meaning that the stake was reduced by 0.89% with the 5,000-share transaction.

The shares most recently traded at $161.21, down $0.52, or 0.32% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 50,000
  • 12-Week # shares sold: 71,627
  • 24-Week # shares sold: 201,739

The average volume for Jazz Pharmaceuticals has been 736,600 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $9.8 billion and is part of the health care sector and drugs industry. Shares are down 2.82% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 324.5. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and premium valuation. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TechTarget (TTGT) - FREE Research Report

Cotoia Michael, who is Chief Operating Officer at TechTarget, sold 13,373 shares at $10.64 on Jan. 15, 2015. Following this transaction, the Chief Operating Officer owned 427,048 shares meaning that the stake was reduced by 3.04% with the 13,373-share transaction.

The shares most recently traded at $10.77, up $0.13, or 1.21% since the insider transaction. Historical insider transactions for TechTarget go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 27,698
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 76,326
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 88,326

The average volume for TechTarget has been 136,800 shares per day over the past 30 days. TechTarget has a market cap of $350.2 million and is part of the technology sector and internet industry. Shares are down 7.12% year-to-date as of the close of trading on Thursday.

TechTarget, Inc. provides specialized online content and brand advertising that brings together buyers and sellers of corporate information technology (IT) products. The company has a P/E ratio of 151.7. Currently, there are 4 analysts who rate TechTarget a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TTGT - FREE

TheStreet Quant Ratings rates TechTarget as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full TechTarget Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null